Last --
Change Today 0.00 / 0.00%
Volume 0.0
BIOCON On Other Exchanges
Symbol
Exchange
BIOCON is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

biocon ltd (BIOCON) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOCON LTD (BIOCON)

Related News

No related news articles were found.

biocon ltd (BIOCON) Related Businessweek News

No Related Businessweek News Found

biocon ltd (BIOCON) Details

Biocon Limited develops and sells biotechnology products for the pharmaceutical sector in India and internationally. It offers active pharmaceutical ingredients, including cardiovascular agents, anti-obesity agents, immunosuppressants, opthalmics, peptides, oral anti-diabetic agents, anti-inflammatory agents, hepatoprotective agents, and probiotics; and biosimilars comprising human insulin, insulin glargine, insulin lispro, insulin aspart, erythropoietin, filgrastim, streptokinase, and monoclonal antibodies. The company also provides branded formulations in the areas of diabetology, oncotherapeutic, nephrology, cardiology, immunotherapy, comprehensive care and bioproducts; and out-licensing services. In addition, it offers contract manufacturing services, including mammalian cell culture fermentation, microbial cell culture fermentation, and synthetic chemistry to small-to-medium sized pharmaceutical and biotech companies; undertakes clinical research activities on discovering new biomarkers; and provides integrated contract research services to support discovery and development, for small and large molecules. The company was founded in 1978 and is headquartered in Bengaluru, India.

7,310 Employees
Last Reported Date: 06/26/14
Founded in 1978

biocon ltd (BIOCON) Top Compensated Officers

Founder, Chairman, Managing Director, Member ...
Total Annual Compensation: 14.1M
Compensation as of Fiscal Year 2014.

biocon ltd (BIOCON) Key Developments

Biocon to Invest USD 200 Million in Insulin-Producing Plant in Malaysia

Biocon announced that it plans to invest USD 200 million in an insulin-producing plant in Malaysia and has agreed to sell Insugen (recombinant human insulin) in Malaysia in co-operation with Chemical Company of Malaysia Berhad (CCM) in early 2015. The company started construction of the manufacturing facility in mid-2012 and has already invested USD 160 million in the first phase of the project, with a remaining USD 40 million to be invested in phase 2.

Biocon Ltd Enters into Strategic Partnership with CytoSorbents for CytoSorb(R) to Treat SIRS and Cardiac Surgery Patients

Biocon Ltd. and CytoSorbents Corporation announced that they have expanded the scope of their strategic partnership for CytoSorbents CytoSorb(R) cytokine reduction therapy to treat patients experiencing severe whole body inflammation, often called a Systemic Inflammatory Response Syndrome (SIRS). Biocon will now have region-wide rights to distribute CytoSorb(R) for all critical care applications in the intensive care unit (ICU) as well as cardiac surgery applications for India and select emerging countries. As part of the expanded agreement, Biocon will also play a prominent leadership role in the generation of new clinical evidence to support the adoption and usage of CytoSorb(R). This includes commitments to conduct and publish results from multiple Investigator Initiated Trials (IITs) and patient case studies.

Biocon Limited Reports Unaudited Consolidated and Standalone Earnings Results for the Second Quarter and Six Months Ended September 30, 2014

Biocon Limited reported unaudited consolidated and standalone earnings results for the second quarter and six months ended September 30, 2014. For the quarter, on consolidated basis, the company reported net sales/income from operations of INR 7,496.9 million compared to INR 7,342.1 million a year ago. Profit from operations before other income, finance cost and exceptional items was INR 1,188.3 million compared to profit from operations before other income, finance cost and exceptional items of INR 1,257.7 million a year ago. Profit from ordinary activities before tax was INR 1,288.4 million compared to profit from ordinary activities before tax of INR 1,371.6 million a year ago. Net profit after tax and minority interest was INR 1,020.5 million or INR 5.12 per diluted share compared to net profit after tax and minority interest of INR 1,021.5 million or INR 5.17 per diluted share a year ago. For the six months, on consolidated basis, the company reported net sales/income from operations of INR 14,685.0 million compared to INR 14,289.7 million a year ago. Profit from operations before other income, finance cost and exceptional items was INR 2,408.4 million compared to profit from operations before other income, finance cost and exceptional items of INR 2,374.2 million a year ago. Profit from ordinary activities before tax was INR 2,669.0 million compared to profit from ordinary activities before tax of INR 2,630.5 million a year ago. Net profit after tax and minority interest was INR 2,049.6 million or INR 10.28 per diluted share compared to net profit after tax and minority interest of INR 1,956.5 million or INR 9.90 per diluted share a year ago. For the quarter, on standalone basis, the company reported net sales/income from operations of INR 5,387.8 million compared to INR 5,341.7 million a year ago. Profit from operations before other income, finance cost and exceptional items was INR 905.2 million compared to profit from operations before other income, finance cost and exceptional items of INR 987.7 million a year ago. Profit from ordinary activities before tax was INR 2,050.1 million compared to profit from ordinary activities before tax of INR 1,188.3 million a year ago. Net profit after tax was INR 1,815.2 million or INR 9.11 per diluted share compared to net profit after tax of INR 898.8 million or INR 4.55 per diluted share a year ago. For the six months, on standalone basis, the company reported net sales/income from operations of INR 10,733.8 million compared to INR 10,570.6 million a year ago. Profit from operations before other income, finance cost and exceptional items was INR 1,761.8 million compared to profit from operations before other income, finance cost and exceptional items of INR 1,843.6 million a year ago. Profit from ordinary activities before tax was INR 3,021.4 million compared to profit from ordinary activities before tax of INR 2,310.6 million a year ago. Net profit after tax was INR 2,561.5 million or INR 12.85 per diluted share compared to net profit after tax of INR 1,776.1 million or INR 8.99 per diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOS:IN 417.20 INR +4.55

BIOCON Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cambrex Corp $21.79 USD +0.17
Depomed Inc $15.69 USD +0.145
Divi's Laboratories Ltd 1,692 INR +19.00
Flamel Technologies SA $17.11 USD +0.105
Piramal Enterprises Ltd 809.65 INR -1.95
View Industry Companies
 

Industry Analysis

BIOCON

Industry Average

Valuation BIOCON Industry Range
Price/Earnings 19.2x
Price/Sales 2.7x
Price/Book 2.5x
Price/Cash Flow 12.8x
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOCON LTD, please visit www.biocon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.